APAC: 3,298 million USD (2030 value); CAGR: 18.3%
Isoxazoline is a relatively new chemical family of five-membered heterocyclic chemical compounds with one oxygen and one nitrogen atom next to each other. Isoxazoline compounds such as fluralaner, afoxolaner, sarolaner, and lotilaner are active components in tick repellents.
Ticks are non-flying insects that are parasites on dogs, cats, and other animals. The host must come into direct touch with a tick in order to become a parasite. Ticks are dangerous to pets because they transmit illnesses such as Lyme disease, Rocky Mountain spotted fever, ehrlichiosis, tularaemia, and STARI (Southern tick-associated rash illness). In order for illnesses to be transferred, a tick must remain attached to a host for several hours. To prevent pets against tick bites, a variety of repellents, insecticides, and growth inhibitors are commercially available.
The isoxazoline class of medicines are oral insecticides that have been approved for the treatment of ectoparasites in companion animals such as dogs and cats. These medications were initially introduced in 2013 as veterinary treatments for ticks and fleas in dogs. Several studies, however, have demonstrated their effectiveness against various veterinary and agricultural parasites. Bravecto, Credlio, Nexgard, and Simparica are examples of FDA-approved isoxazoline medications.
Innovations on current medications for new indications in oral and topical formulations, as well as increased awareness of ectoparasite prevention and control of fleas and ticks, are expected to drive market expansion. The market is divided into three sections: product type, pet kind, and geography.
There has been an increase in pet animal care spending in recent years. The American Pet Products Association, Inc. (APPA) claims that "In 2019, the US Pet Industry spent a total of USD 97.1 billion. Similarly, the US Pet Industry Expenditure in 2020 was USD 103.6 billion. In 2020, USD 31.4 billion was spent on veterinary care and product sales, with a projected USD 32.2 billion in 2021."
Ticks and fleas are common parasites in pets like dogs and cats. Several commercially available medications can help dogs and cats avoid and control tick and flea infestations. The market for isoxazoline, a new family of ectoparasite medications for dogs and cats, is increasing. The key element driving demand for isoxazoline medications is growing spending on pet care and increased pet adoption.
Tick and flea prevention and control products are readily accessible on the market. The EPA and the US Food and Drug Administration regulate some of these goods. These products are deemed safe and effective in cats and dogs by the US Food and Drug Administration. Isoxazoline medications, on the other hand, must be licenced for use on animals by the US FDA, the European Medicines Agency, and Canada Health.
The US FDA issued a warning in September 2018 about flea tablets and chews that have been linked to neurological issues. In certain dogs and cats, these products cause neurological problems like ataxia, seizures, and muscular tremors. To some extent, these laws limit the expansion of the market for these medications.
The use and safety of isoxazoline medications are being researched by pharma companies among pet owners and veterinarians. Isoxazoline neurotoxicity was not shown to be unique to ticks and fleas, according to these surveys. Manufacturers have altered the labelling for several medications as a result of these studies. Isoxazoline medications are safe and effective in cats and dogs, according to the US FDA.
Based on product type, the worldwide isoxazoline drugs market is divided into fluralaner, sarolaner, lotilaner, and afoxolaner. In 2021, afoxolaner medicines sold more than any other drug on the market, and they had the biggest market share.
The market is divided into two categories: dogs and cats. During the years 2020–2021, the number of dogs and cats adopted skyrocketed. According to a poll performed by the Humane Society of the United States, over half of all American households own at least one dog. The dogs' category took the bulk of the market share in 2021 and is predicted to increase at a CAGR of 18.11% during the forecast period.
In the market for isoxazoline drugs, Asia-Pacific is expected to have the largest share. During the forecast period, the market is expected to be propelled by rising adoption rates in countries such as India and China, as well as increased public awareness of pet care. Growing pet-care spending in India is expected to create plenty of opportunities. "The Indian animal healthcare industry is anticipated to reach approximately Rs. 5,500 crores (USD 770 million) (2020)," according to the Indian Federation of Animal Health Companies.
Companion animals account for around 5% of all animal healthcare spending. The paucity of isoxazoline producers in these areas also creates an opportunity for existing businesses. Furthermore, firms are aiming to have their treatments approved in India and China. Such characteristics are expected to present manufacturers with significant potential to increase their presence in these emerging countries.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|